Clinical Trials
23 trialsNCT07146919 2026-04-23
ANGELICA
Centre Leon Berard
Phase 1/2 Withdrawn
NCT07060365 2026-04-03
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
AstraZeneca
Phase 1/2 Withdrawn
NCT06545617 2026-01-07
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Bio-Thera Solutions
Phase 1/2 Withdrawn
NCT06393751 2025-06-03
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT05672095 2025-05-23
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT02756130 2025-05-13
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT06385548 2025-04-01
LiDer
Vall d'Hebron Institute of Oncology
Phase 1/2 Withdrawn
NCT05714306 2025-03-05
CHUV-OVACURE
Centre Hospitalier Universitaire Vaudois
Phase 1/2 Withdrawn
NCT03197584 2025-02-21
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03735589 2023-11-22
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT03634150 2021-10-26
Safety and Efficacy of IV Nerofeâ„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
Immune System Key Ltd
Phase 1/2 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT04389229 2020-12-16
OVSTAR
Immetacyte Ltd
Phase 1/2 Withdrawn
NCT01097239 2020-11-20
Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer
Imperial College London
Phase 1/2 Withdrawn
NCT02713984 2020-03-19
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Southwest Hospital, China
Phase 1/2 Withdrawn
NCT03281681 2019-10-18
REPROVe
Kintara Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT00562185 2017-11-20
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT01176500 2017-07-02
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT00603460 2017-05-02
DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer
University of Pennsylvania
Phase 1/2 Withdrawn
NCT00452920 2016-12-15
Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer
University of Miami
Phase 1/2 Withdrawn
NCT01624493 2015-12-23
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Hoosier Cancer Research Network
Phase 1/2 Withdrawn
NCT01880996 2015-06-11
Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies
Sheba Medical Center
Phase 1/2 Withdrawn
NCT01982487 2013-12-18
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
Roswell Park Cancer Institute
Phase 1/2 Withdrawn